Industry
From U.S. (Toll Free) : +16467917070    |   UK : +442030260021     |    sales@businessmarketinsights.com

Asia-Pacific Dermatology OTC Medications Market Forecast to 2028 – COVID-19 Impact and Analysis – by Product Type (Tablets and Capsules, Gels, Creams and Ointments, and Others), Route of Administration (Topical and Oral), Indication (Dermatitis, Acne, Psoriasis, Skin Bleaching, Fungal Disease, Warts, and Others), and Distribution Channel (Online Distribution and Offline Distribution) 

Report Code :  BMIRE00025070
No. of Pages :  214
Published Month :  Jun 2022
Category :  Life Sciences
$299 per month

Best Plan
  • All Reports in One Industry
  • All Reports Read Access
  • Subscription Duration : 12 Months
  • Monthly New Reports Added
  • $1200 Yearly Saving

The APAC dermatology OTC medications market is expected to grow from US$ 3,496.75 million in 2021 to US$ 5,296.25 million by 2028; it is estimated to grow at a CAGR of 6.1% from 2021 to 2028.

According to Statista, the OTC pharmaceuticals market generated US$ 3,773 million in November 2018. In 2018, the average revenue per person in the OTC pharmaceuticals industry was US$ 2.79. Similarly, the OTC market was worth US$ 125 billion in 2019 and is expected to grow at a rate of 4–5% over the next few years, according to The Lubrizol Corporation firm. Some patients continue to use brand-name prescriptions despite the cost difference due to perceptions or previous experiences with generic medications, increasing consumer spending, patient discontent, and declining adherence. Higher competition in the generic product industry lower drug prices and increases access to affordable healthcare. Generics are typically 80‒85% cheaper than branded products. According to the one association, 4 billion generic prescriptions were filled in 2018, accounting for 90% of all prescriptions filled in the countries across the region. However, this accounted for only 22% of total medication spending. Thus, the growing OTC drugs market will create lucrative opportunities for the APAC dermatology OTC medications market.

 

With the new features and technologies, vendors can attract new customers and expand their footprints in emerging markets. This factor is likely to drive the APAC dermatology OTC medications market. The APAC dermatology OTC medications market is expected to grow at a good CAGR during the forecast period. 

 

APAC Dermatology OTC Medications Market Revenue and Forecast to 2028 (US$ Million)    


APAC Dermatology OTC Medications Market Segmentation       

 

The APAC dermatology OTC medications market is segmented into product type, route of administration, indication, distribution channel, and country. Based on product type, the market is segmented into tablets and capsules, gels, creams and ointments, and others. The creams and ointments segment dominated the market in 2020; however, the tablets and capsules segment is expected to be fastest growing segment during the forecast period. Based on route of administration, the market is segmented into topical and oral. The topical segment dominated the market in 2020; however, the oral segment is expected to be a faster growing segment during the forecast period. Based on indication, the market is segmented into dermatitis, acne, psoriasis, skin bleaching, fungal disease, warts, and others. The acne segment dominated the market in 2020 and is expected to be the fastest growing during the forecast period. The dermatitis segment is further segmented into atopic dermatitis, contact dermatitis, and others. The acne segment is further segmented into non-inflammatory acne and inflammatory acne. The psoriasis segment is sub segmented into plaque psoriasis, guttate psoriasis, and others. The fungal disease is further segmented into athlete's foot, ringworm, fungal nail infections, and others. Moreover, the warts segment is further segmented into common warts, flat warts, and others. Based on distribution channel, the market is segmented into online distribution and offline distribution. The offline distribution segment dominated the market in 2020; however, the online distribution segment is expected to be a faster growing segment during the forecast period. The offline distribution is further segmented into retail and hospital pharmacies and super and hypermarkets. Based on country, the market is segmented into China, India, Japan, South Korea, Australia, and the Rest of APAC.      

 

Bausch Health Companies Inc.; Bayer AG; Dr. Reddy's Laboratories; Galderma; GlaxoSmithKline plc.; Johnson and Johnson Services, Inc.; LEO Pharma A/S; Perrigo Company plc; and Viatris Inc. are among the leading companies in the APAC dermatology OTC medications market. 

  1. Bausch Health Companies Inc.
  2. Bayer AG
  3. Dr. Reddy's Laboratories
  4. Galderma
  5. GlaxoSmithKline plc.
  6. Johnson and Johnson Services, Inc.
  7. LEO Pharma A/S     
  8. Perrigo Company plc
  9. Viatris Inc.  
  • Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the APAC dermatology OTC medications market.        
  • Highlights key business priorities in order to assist companies to realign their business strategies
  • The key findings and recommendations highlight crucial progressive industry trends in the APAC dermatology OTC medications market, thereby allowing players across the value chain to develop effective long-term strategies
  • Develop/modify business expansion plans by using substantial growth offering developed and emerging markets
  • Scrutinize in-depth APAC market trends and outlook coupled with the factors driving the dermatology OTC medications market, as well as those hindering it
  • Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing, and distribution  


Contact Us : +442081254005 | Email : sales@businessmarketinsights.com
© Copyright 2025 - Business Market Insights. All rights reserved